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Hypothesis and Objectives 
The overall goal of this proposal is to determine expression of the tumor suppressor genes PTEN, 
p16, Rb, and p53 in canine osteosarcoma using immunohistochemistry.    
Hypothesis: Loss of tumor suppressor genes PTEN, p16, Rb, and p53 protein expression occurs 
frequently in canine osteosarcoma.  
 
Objective 1:  Identify cases of canine osteosarcoma presented to The Ohio State College of 
Veterinary Medicine Veterinary Medical Center between the years 2003-2008 and abstract 
the associated clinical information from medical records. 
A medical record database including each affected patient’s related clinical information will be 
constructed.  Relevant patient information includes, but is not limited to, age, breed, sex, date of 
diagnosis, date of death, cause of death, and treatment protocol used. 
 
Objective 2:  A tissue microarray (TMA) containing each dog’s osteosarcoma tumor biopsy 
will be constructed from formalin-fixed paraffin embedded (FFPE) blocks.   
TMAs will be constructed from individual patient FFPE tissue blocks. TMAs will be constructed 
with the assistance of the Immunohistochemistry Core in the College of Veterinary Medicine. 
Objective 3: Determine protein expression of selected tumor suppressor genes using 
immunohistochemistry (IHC).   
IHC will be performed on canine osteosarcoma TMAs for selected tumor suppressor proteins 
(PTEN, Rb, p16, and p53). The incidence of loss of tumor suppressor protein expression in 
canine osteosarcoma tumor samples as determined by IHC will be determined. 
 
Significance and Justification 
In order to optimize care for human and canine patients affected with cancer, it is important to 
identify dysregulated cancer associated genes that might be used as prognostic indicators or 
could be used to help develop more effective treatments.  Since the introduction of adjuvant 
chemotherapy to treat potential micrometastatic disease and subsequent modifications of 
adjuvant cytotoxic chemotherapy protocols, no significant advances in the treatment of canine 
osteosarcoma have been made for the past 20 years. [15]   Because the biologic behavior, 
including metastatic potential, depends significantly on the underlying genetics of the tumor, 
including the expression of tumor suppressor genes, it is important to obtain a better 
understanding of the incidence of tumor suppressor gene dysregulation in osteosarcoma in dogs.  
Importantly, the signaling pathways associated with tumor suppressor genes are potential targets 
for therapy and their expression may be correlated with clinical outcomes.  
 By determining which tumor suppressor proteins are being aberrantly expressed, future 
therapies can be targeted to that signaling pathway.  For example, mutations affecting the pRb 
pathway make cells refractory to antigrowth factors that normally inhibit cells from entering the 
G1 phase of the cell cycle. [5] Thus, restoring Rb function might be one form of anticancer 
treatment. 
 In conclusion, studying signaling pathways and gene families linked to cancer at the molecular 
level has revealed that optimal treatment methods for different types of cancer are not universal.  
There are many different genes linked to cell proliferation and cell growth inhibition, and an 
abnormality in any one of these genes could result in uncontrolled cell growth. Therefore, based 
on the actions of the genes involved, responses to different treatments in different patients are 
expected to vary.  By understanding which cancer genes are dysregulated in a particular tumor, 
the prognostic significance of that dysregulation can be determined and treatment protocols can 
be established so that they are personalized to each patient.  In addition, identifying these 
prognostic indicators will then identify more targets for future studies. 
   
Background 
Canine and Pediatric Osteosarcoma 
Osteosarcoma (OS) is a heterogeneous tumor of mesenchymal origin accounting for 
approximately 80% of bone tumors arising in dogs.   While any dog can be afflicted with OS, 
large breed dogs between the ages of 7-10 years are most commonly affected. [16] The most 
frequent anatomic site for OS occurrence is in the appendicular skeleton, but it can also occur in 
the vertebral column, skull, and pelvic bones of the axial skeleton.  Although amputation, 
chemotherapy, and radiation therapy are available treatment options, the long-term prognosis is 
poor.  Because the onset of OS is sudden, many diagnoses are not made until the tumor has  
already metastasized [13]. The lungs are the most frequent site of metastasis; however, other soft 
tissue and bone metastases are also possible.  Dogs that undergo amputation and respond well to 
chemotherapy have an estimated median survival time of about one year.  Survival times are 
significantly lower without amputation or treatment.  A patient who receives no treatment 
generally has a 1-3 month survival time. [16]    
A significant breakthrough in the field of comparative oncology came with the release of the 
canine genome in 2005 and subsequent application of genomic methods to understanding canine 
tumor biology. [17] It is now known that cancer related genes and pathways associated with 
cancer in dogs are similar to those associated with cancer in humans. Consequently, 
spontaneously occurring cancer in pet dogs is a highly relevant model for studying similar 
cancers in people.  While OS in dogs is more prevalent among older dogs, human OS primarily 
affects the pediatric age group at a rate of 8.7 children per million. [2] Human OS often occurs in 
the metaphyseal regions of the long bones (same as dogs), and generally occurs in adolescence. 
[2] Although the initiation of multidrug chemotherapy and more efficient surgical methods in the 
1980s increased the rate of human nonmetastatic OS to 65%, OS treatment in humans since that 
time has not improved. [2] Because canine OS is similar to human OS in regards to its metastatic 
and aggressive nature, histology, mode of treatment, similarity in treatment response, and 
progression, dogs are an excellent model for comparative study.  
 
 
Tissue Arrays 
An efficient method for analyzing 
and comparing a large number of 
tissue samples in a high throughput 
fashion is to construct a tissue array.  
A tissue array is constructed by 
using a high precision instrument to 
punch a small portion of tumor 
tissue preserved in a formalin fixed 
paraffin embedded block (FFPE) and 
then inserted it into a recipient 
paraffin block.  Because a large 
number of tumor samples can be 
inserted into a single recipient paraffin block, constructing a tissue array allows numerous tumor 
biopsies to be assayed simultaneously, thus saving time, cost and ensuring consistent treatment 
methods among all samples.    
In order to construct a tissue array, slides containing the tumor biopsy must be reviewed to 
confirm the diagnosis and to mark the tumor location on the slide.  Then, the slide is matched to 
its original block to locate the proper location for “punching” (sampling) the original block.  The 
punching instrument can remove samples as small as 0.6 mm and as large as 2.0 mm. The 
arraying device deposits precise amounts, “cores”, of each sample into premade holes in the 
recipient block (Figure 1 and Figure 2).  The completed tissue array can then be used for 
essentially any application for which individual FFPE tissue sections are normally used, e.g. 
 
Figure 1. A high precision instrument is used to punch a 
sample of fixed tissue and transfer it to a recipient block. 
A slide is then made from the block, allowing the 
samples from different patients to be tested 
simultaneously on a single slide. 
	
immunohistochemistry, in situ hybridization, fluorescence in situ hybridization (FISH); however, 
the TMA allows up to hundreds of samples from different patients can be evaluated on a single 
slide.   
 
 
Figure 2. TMA construction. 1. Tissue preserved in formalin fixed paraffin-embedded donor blocks. 2. A 
manual high-precision instrument removes a cylindrical core from representative tissue in the donor 
block. 3. The cores are inserted into a recipient paraffin block. 4. Slides are constructed for analysis by 
cutting 0.5µm sections from the TMA block and staining with H&E.   
 
Tumor Suppressor Genes Implicated in Canine OS Pathogenesis 
Tumor suppressor genes are genes that protect a cell from uncontrolled cell division deregulated. 
When deregulated or mutated to cause a loss in gene function, the cell can progress to cancer. 
Tumor suppressor proteins typically have a repressive effect on the cell cycle or promote 
apoptosis. Several tumor suppressor genes have been identified previously to be dysregulated in 
canine OS; however, the overall prevalence of tumor suppressor gene dysregulation and its 
prognostic significance in canine osteosarcoma has not been evaluated. 
p53 
The tumor suppressor gene p53 has been called the “policeman” of the cell cycle, or “guardian of 
the genome”.  If chromosomal DNA becomes damaged, p53 halts the cell division process until 
repair can be made, or directs the cell towards apoptosis if the damage is irreparable.  When the 
p53 gene is damaged or mutated, cells can replicate uncontrollably.  The locations and types of 
mutations seen in the p53 gene in dogs are nearly identical to those seen in the human p53 gene. 
[10] Although p53 can be inactivated by mutations such as insertions or deletions, point mutations 
are the most common mutation seen in human OS. Past studies have shown that p53 is 
inactivated in approximately 50% of human cancers and 60% of canine cancers. [7][10]   In dogs, 
p53 is over-expressed in 84% of OS from appendicular locations and 54% of OS from axial 
locations. [7] Normally, the p53 protein is not stable enough to be seen on IHC.  When the p53 
becomes mutated, the protein becomes abnormally stable and IHC can readily detect p53 in the 
cell’s cytoplasm. [6]  
 
Rb  
The retinoblastoma susceptibility gene codes for the retinoblastoma protein (Rb) which regulates 
passage from G1 to S phase of the cell cycle. Rb regulates cell growth by regulating the amount 
of available transcription factors from the E2F family. [6][7] Cyclin-dependent kinases (CDKs) 
block Rb phosphorylation when cell growth and DNA synthesis need to be arrested.  A mutation 
that causes inhibition of CDKs or Rb phosphorylation allows for unregulated cell growth, and 
occurs in many human cancers.  Although Rb originates in the cytoplasm of the cell, it carries 
out its function in the nucleus.  Decreased, or absent, expression of the Rb protein has been 
reported in canine OS cell lines. [7][8] 
 
PTEN 
Another tumor suppressor gene whose dysregulation contributes to the development of cancer is 
PTEN.  By antagonizing the phosphoinositide-3 kinase pathways (PI3K), PTEN negatively 
impacts cell survival signals and growth, and may have inhibitory affects on metastases from 
tumor cell invasion and tumor directed angiogenesis. [6][8] When PTEN is mutated, the PI3K 
pathways are no longer inhibited, promoting cell survival and proliferation. Three of 5 canine OS 
cell lines and 10 of 15 canine OS tumors exhibited decreased or absent PTEN expression in one 
study. [8] 
 
P16 
The tumor suppressor gene p16 functions as a CDK inhibitor that prevents cell cycle progression 
and directs cells toward apoptosis. [6] When p16 protein expression was evaluated using 
immunocytochemistry in canine melanoma, staining was primarily cytoplasmic and reduced 
expression was seen in 21 of 26 melanoma samples. [6] When evaluated in canine OS, p16 
expression was not detectable in 4 of 5 canine OS cell lines. [7] 
 
 
Table1.  Tumor Suppressor Genes in Canine Osteosarcoma 
 
 
Gene 
 
 
Function 
 
 
Significance 
 
References 
Rb 
Regulator of cell growth 
between G1/S phases of 
cell cycle 
Inhibition of CDKs or Rb 
phosphorylation allows for 
unregulated cell growth. In humans, 
one thousand times greater risk to 
develop OS if Rb is hereditary. 
[2] 
P53 
Promotes apoptosis and 
policeman of cell cycle 
progression 
Mutation is correlated with 
unregulated cell growth and a poor 
outcome. Inactivated in 50% human 
cancers and 60% of canine cancers. 
[2][3] 
P16 
Prevents cell cycle 
progression past the G1 
phase and directs cell 
towards apoptosis 
Mutation causes unregulated cell 
growth. Family gene INK4A is 
deleted in 10% of patients. 
[6][2] 
PTEN 
Antagonizes the 
phosphoinositide-3 
kinase pathways (pI3k) 
Mutation increases chance of 
invasion, increases tumor cell 
survival, and tumor directed 
angiogenesis. 
[6][8] 
 
Materials and Methods  
Case selection and tissue array  
Cases were identified by a computer-based search of The Ohio State University College of 
Veterinary Medicine Pathology Archives for diagnoses of OS from the years 2003-2008.  Two-
hundred twenty-one cases were selected and reviewed by a board certified veterinary pathologist. 
Of the 221 cases reviewed, material was available for use from 165 of them.  Patient  
 
 
information including date of diagnosis and biopsy, breed, sex, cause of death, treatment method, 
survival time, disease-free interval, and age were recorded in a spreadsheet.  Missing or 
unknown follow-up information was provided by the referring veterinarian.  
Prior to constructing the tissue array, hematoxylin and eosin (H&E) stained slides were reviewed 
by a board certified pathologist who confirmed the diagnosis and type of OS, and marked the 
target area for coring that included a representative area of tumor.  The target area on the slide 
was matched to the FFPE donor block and three 1.5 mm punches of tumor were removed and 
inserted into a recipient block.   
 
Immunohistochemistry 
Slides are deparaffinated in xylene, 100% ethanol, 95% ethanol, 70% ethanol, and water.  Slides 
awee then incubated in Target Retrieval solution (Dako) at a 1:10 dilution in a decloaking 
chamber. Slides were then heated at 125˚C for 30 seconds, and then cooled to 90˚C for 10 
seconds. After the slides were cooled at room temperature for 10 minutes, they were placed in 
3% H2O2 for 10 minutes to quench endogenous peroxidase activity. [10] To prevent nonspecific 
antibody bonding, the slides were then incubated with 3% nonfat dry milk (NFD) mixed with 
150 mL phosphate buffered saline (PBS) for 30 minutes. Control slides were incubated with an 
irrelevant, isotype matched negative control.  For PTEN detection, a monoclonal mouse anti-
human antibody (Santa Cruz Biotechnology, INC) was used.  Sections were incubated at a 1:100 
dilution for 2 hours at room temperature.  For detection of p16, a polyclonal rabbit anti-human 
antibody (Santa Cruz Biotechnology, INC) was used.  Sections were incubated at a 1:100 
dilution for 2 hour.s  A mouse monoclonal anti-human retinoblastoma protein antibody (BD 
Pharmingen TM) was diluted 1:100 and incubated for 2 hours for Rb detection.   For p53 
detection, the polyclonal rabbit anti-p53 antibody was diluted 1:100 and incubated for 2 hours. 
After the primary antibody incubation period, slides were transferred to PBS and then incubated 
with the secondary antibody for 30 minutes (VectaStain® Universal Elite ABC Kit, Vector 
Laboratories).  Slides were then transferred to PBS and then incubated with Reagent A and 
Reagent B (VectaStain® Universal Elite ABC Kit, Vector Laboratories) for 30 minutes.  The 
sections were then incubated with DAB tablets (Sigma, St. Louis) prepared in tap water for 5 
minutes, then counterstained with hematoxylin, dehydrated, and cover-slipped.  
 
Immunohistochemistry Scoring  
Immunohistochemical staining was scored semi-quantitatively the following way: 
Table 2:  Semi-quantitive Immunohistochemical Scoring 
Staining  Distribution 
Negative (<10% cells):0  No staining: 0 
Positive (>10% cells): 1  Nuclear: 1 
  Cytoplasmic: 2 
Intensity  Nucleolar: 3 
Weak: 1  Cytoplasmic and nucleolar: 4 
Moderate: 2  Cytoplasmic and nuclear: 5 
Intense: 3    
  Cannot be interpreted:   CBI 
 
 
 
 
Results  
Table 3: Immunohistochemistry Analysis of TS genes PTEN, p16, Rb, and p53 
Gene   PTEN        p16         Rb          p53 
  N= % N= %  N= %  N= % 
Samples 147   149   146   151   
Staining                 
Positive 92 62.6 100 67.1 100 68.5 125 82.8 
Negative 55 37.4 49 32.9 46 31.5 26 17.2 
Distribution                 
Nucleolar 20 13.6 0 0 0 0 0 0 
Cytoplasmic and 
Nuclear 26 17.7 35 23.5 81 55.5 98 65 
Cytoplasmic 24 16.3 65 43.6 8 5.5 25 16.6 
Nuclear  1 0.7 0 0 11 7.5 2 1.3 
Cytoplasmic and 
Nucleolar 21 14.3 0 0 0 0 0 0 
Intensity                 
Weak 33 22.4 20 13.4 31 21.2 35 23.2 
Moderate  35 23.8 21 14.1 36 24.7 32 21.2 
Intense  24 16.3 59 40 33 22.6 58 38.4 
Out of 146 samples that were evaluated for Rb, 100 (68.5%, Figure 3a) stained positive.  The 
samples stained primarily cytoplasmic and nuclear (55.5%) and were mostly moderate in 
intensity (24.7%).  Of the 147 samples that were evaluated for PTEN, 92 (62.6 %) stained 
positive. The primary staining pattern was cytoplasmic and nuclear at 17.7% (Figure 3b), 
followed closely behind by cytoplasmic (16.3 %) and cytoplasmic and nucleolar (14.3 %) and 
was moderate in intensity at 23.8%. 
                   Figure 3a                                                Figure 3b 
     
Figure 3ab. Figure 3a shows Rb intense nuclear/cytoplasmic staining.  Figure 3b shows PTEN intense 
nuclear/nucleolar staining.  
 Of the 151 samples that were evaluated for p53, 125 (82.8%) stained positive.  The primary 
staining pattern was cytoplasmic and nuclear (65%) and most were intense in staining (38.4%). 
Of the 149 samples evaluated for p16, 100 (67.1%) stained positive. The location of stain was 
primarily in the cytoplasm (65%) and the intensity score was intense (40%).  
 
Discussion 
Other studies suggest that tumor suppressor genes are dysregulated in canine osteosarcoma.  
However, due to the limited sample size of these studies, the frequency of dysregulation 
remained unknown. Usually, loss of expression of tumor suppressor genes is thought to promote 
cancer formation.  P53 is an exception as positive expression tends to be more indicative of gene 
dysregulation and the promotion of cancer. A previous study looking at PTEN expression found 
that 10 of 15 (66.7%) OS tumors showed variable or negative PTEN staining [8].  The results of 
our findings showed negative staining in 55 of 147 samples (37.4%).  Also, p16 was lost in 4 of 
5 (80%) of cases according to one study [7]. The results of our study found p16 loss in 49 of 149 
32.9%) cases.   Loss of Rb expression has been showed in 70% of sporadic OS[2]. Our findings 
showed negative Rb expression in 46 of 146 cases (31.5%).  Another study reviewing p53 
expression found negative p53 expression in 44 of 125 (35.2%) OS tumors[10].  The results of our 
study showed negative p53 expression in 26 of 151 (17.2%).   
Conclusion 
Tumor suppressor genes found to be commonly dysregulated in human osteosarcoma have also 
shown to be abherrantly expressed in canine osteosarcoma. Altered expression of these tumor 
supressor genes has potential prognostic and therapeutic significance for disease and treatment of 
dogs with osteosarcoma.  
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